Optimizing Protein Intake in Older Americans With Mobility Limitations

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01275365

Acronym

OPTIMen

Enrollment

Registered

2011-01-12

Start date

2011-05-31

Completion date

2017-01-19

Last updated

2021-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mobility Limitation

Keywords

Mobility Limitation, Low Protein Intake, Older Men, Testosterone

Brief summary

This will be a randomized, placebo-controlled, parallel group, double blind, clinical trial in community dwelling, older men, 65 years of age or older, who have mobility limitation and low protein intake. The study will have a 2 X 2 factorial design, which will allow us to investigate the effects of dietary protein intake and testosterone separately and together.

Detailed description

The recommended dietary allowance (RDA) for protein, set at 0.8 grams/kg/day for adult men and women, has engendered debate and many experts advocate protein intakes substantially above the RDA to help maintain muscle anabolism in older individuals. It is not known whether increasing protein intake in older Americans, whose current intake is below the RDA, increases skeletal muscle mass, muscle performance and physical function. Our first aim is to determine whether administration of 1.3 g/kg/day of protein, compared to the RDA (0.8 g/kg/day), will result in greater improvements in lean body mass, maximal voluntary muscle strength and power, and self-reported and performance-based measures of physical function in older men. Our second aim is to determine whether the gains in lean body mass, maximal voluntary strength and self-reported and performance-based measures of physical function during testosterone administration are greater with 1.3 g protein than with the RDA in older men on a eucaloric diet. We will conduct a randomized, placebo-controlled, double-blind trial using a 2 X 2 factorial design. Community dwelling men, 65 years or older, who have self-reported mobility limitation, a daily protein intake of \<0.8 g/kg/day and no contraindications for testosterone therapy, will be randomly assigned to one of four groups: placebo injections plus protein 0.8 g/kg/day; placebo injections plus protein 1.3 g/kg/day; testosterone enanthate 100 mg weekly plus protein 0.8 g/kg/day; testosterone enanthate 100 mg weekly plus protein 1.3 g/kg/day. Treatment duration will be 6 months. The primary outcome is change in lean body mass from baseline to 6 months, measured by dual energy X-ray absorptiometry. Secondary outcomes include change in maximal voluntary strength in leg and chest press exercises, leg power, self-reported (physical function domain of SF-36) and performance-based measures of physical function (6-min walking distance and speed, stair climbing power, and load carrying), fatigue, well-being and affectivity balance. Safety measures include urinary calcium excretion, hematocrit, prostate specific antigen (PSA) and prostate examination.

Interventions

DRUGTestosterone enanthate

Testosterone enanthate 100 mg intramuscularly weekly

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

65 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Community-dwelling men 65 years of age or older 2. A score of 3-10 on the short physical performance battery (SPPB) 3. Daily protein intake less than the recommended daily allowance of 0.83 g/kg/day (from 3 24-hour food recalls) 4. Able to give informed consent

Exclusion criteria

1. History of prostate or breast cancer 2. American Urological Association \[AUA\] symptom index score of \>19 3. Prostate specific antigen (PSA) \>4 ng/ml in White men or \>3 ng/ml in Black men 4. Prostate specific antigen (PSA) \> 4 ng/ml in non-Black men or \>3 ng/ml in Black men. These subjects may be enrolled if they have a negative transrectal biopsy within the past year. 5. Myocardial infarction or stroke within the last 6 months 6. Uncontrolled congestive heart failure, based on the study physician's evaluation 7. Serum creatinine \> 2.0 mg/dL; men on any kind of dialysis will be excluded. 8. History of celiac disease, Crohn's disease, or ulcerative colitis 9. History of any malignancy requiring treatment within the previous 2 years, except non-melanic skin cancers. Men with cancers who have not required active treatment within the past two years and who have not had disease recurrence within the past two years may be enrolled at the discretion of the study physician. 10. Neuromuscular diseases: motor neuron diseases, multiple sclerosis, adult muscular dystrophies, and myasthenia gravis 11. History of stroke with residual limb weakness that affected the individual's ability to walk; subjects with history of stroke who do not have residual limb weakness may be enrolled. 12. Schizophrenia, bipolar disorder, or untreated diagnosed depression. Subjects with unipolar depression who are on an antidepressant medication are eligible. 13. TSH levels \<0.4 or \>5 mlU/L 14. Systolic blood pressure (BP) \>160 or diastolic BP \>100 mm Hg (average of 2 measurements taken at Visit 1) 15. Hemoglobin A1c \>8.0% or taking insulin. Men with diabetes mellitus whose A1C is less than 8.0% or who are not taking insulin will be eligible. 16. Mini-Mental Status Exam \[MMSE\] \<24 17. Body mass index (BMI) less than 20 or greater than 40 kg/m2 18. Not willing to eat all of the following: red meat, eggs, poultry, fish and shellfish 19. Allergy to sesame, peanuts, soy, gluten or shellfish 20. Current alcohol use \>21 drinks/week based on self-report 21. Confinement to a wheelchair 22. Use of anabolic therapies (Testosterone, DHEA, androstenedione, rhGH) within the past year 23. Current use of levodopa or anticoagulants 24. Current enrollment in a structured weight management program or participation in any weight intervention studies in the last 90 days 25. Serum ALT and AST greater than 3 x upper limit of normal 26. Hematocrit \< 30% or \>48% 27. Subject is not able to eat 3 frozen study meals per day for 6 months 28. Subject is unwilling to stop current nutritional supplements 29. Progressive intensive resistance training within 12 weeks of screening 30. Non-compliant with run-in diet and/or supplement

Design outcomes

Primary

Measure	Time frame	Description
Change in Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DXA)	6 months from baseline	Primary outcome is change in lean body mass, measured by dual energy X-ray absorptiometry (DXA)

Secondary

Measure	Time frame	Description
Change of Leg Press Power	6 months from baseline	Muscle Performance measured using Power of hip and knee extension by Bassey's leg rig.
Change of 6-minute Walking Distance	6 months from baseline	Tests of Physical Function and Task-Specific Performance measured by 6-min walking distance
Change of Stair Climbing Tests	6 months from baseline	Tests of Physical Function and Task-Specific Performance measured by Stair-climbing power +/- 20% load carry. Physical Function was evaluated using two tests of stair climb power using an indoor 12-step staircase. One test consisted of ascending the 12-steps as rapidly as possible without running (unloaded stair climb) while the second test required participants to carry a load equivalent to 20% of their baseline body weight evenly distributed in two canvas tote bags (loaded stair climb). Time to ascend the stairs was measured electronically with a digital clock and switch mats placed at the base of the steps and on the 12th step. Power in watts is calculated by the following: \[body weight (kilograms) \* distance (meters)/ (time/60)\] /6.12.
Change of 50-meter Loaded Walking Test	6 months from baseline	Tests of Physical Function and Task-Specific Performance measured by 50-meter timed walk + 20% load carry. Physical Function was evaluated using test of 50-meter loaded walking speed. The test required participants to carry a load equivalent to 20% of their baseline body weight evenly distributed in two canvas tote bags. Time was measured electronically with a digital clock. Speed in meters per second is calculated by the following: 50/time.
Change of Maximal Voluntary Strength	6 months from baseline	Tests of Muscle Performance: (1) Maximal voluntary strength measured by 1-repetition maximum method in leg press; (2) Maximal voluntary strength in chest press; this exercise was chosen because it involves the large muscle groups of the upper extremities.
Change of Psychological Well Being Index (PGWBI)	6 months from baseline	The PGWBI is a 22-item health-related Quality of Life (HRQoL) questionnaire developed in US which produces a self-perceived evaluation of psychological well-being expressed by a summary score. The 22 items are grouped in 6 dimensions. A global score is computed as the sum of all items with range of 0-110. A higher score yields better performance.
Change of Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale	6 months from baseline	The FACIT Fatigue Scale is a 13-item questionnaire that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point scale (4 = not at all fatigued to 0 = very much fatigued). Score ranges 0-52. The higher the score, the better the quality of life.
Change of Derogatis Affective Balance Scale (DABS)	6 months from baseline	The Derogatis Affects Balance Scale (DABS) is a multidimensional self-report mood and affects inventory comprised of 40 adjective-items using a 5-point Likert style scale. The DABS global scores consist of the Positive Total score (PTOT), Negative Total score (NTOT), where The Positive Affects Total (PTOT) is defined as the sum of all scores on the four positive affects dimensions of joy, contentment, vigor and affection, ranging 0-80. Similarly, the Negative Affects Total (NTOT) is represented as the sum of scores on the four negative dimensions of anxiety, depression, guilt and hostility, ranging 0-80. The Affects Expressiveness Index (AEI) is defined as the sum total of PTOT and NTOT, ranging 0-160. Higher score yields stronger affective intensity.
Change of Self-reported Physical Function Domain of Short Form Health Survey (SF-36)	6 months from baseline	36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Physical function domain of the Medical Outcomes Study Short Form-36 (SF-36) contains 10 items with the score range of 0-100. Higher score yields better performance.

Countries

United States

Participant flow

Participants by arm

Arm	Count
Placebo/Low Protein Placebo injections weekly; 0.8 g/kg/day protein	24
Placebo/High Protein Placebo injections weekly; 1.3 g/kg/day protein	24
Testosterone/Low Protein Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly	22
Testosterone/High Protein Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly	22
Total	92

Baseline characteristics

Characteristic	Placebo/Low Protein	Total	Testosterone/High Protein	Testosterone/Low Protein	Placebo/High Protein
Age, Continuous	71.3 years STANDARD_DEVIATION 4.2	73.0 years STANDARD_DEVIATION 5.8	76.0 years STANDARD_DEVIATION 7.9	71.0 years STANDARD_DEVIATION 3.6	73.5 years STANDARD_DEVIATION 5.7
Body Mass Index (BMI)	31.1 kg/m^2 STANDARD_DEVIATION 4.2	30.3 kg/m^2 STANDARD_DEVIATION 4.9	29.0 kg/m^2 STANDARD_DEVIATION 5	31.4 kg/m^2 STANDARD_DEVIATION 5.5	29.6 kg/m^2 STANDARD_DEVIATION 4.6
Body weight	95.3 kg STANDARD_DEVIATION 12.5	91.8 kg STANDARD_DEVIATION 16.2	87.2 kg STANDARD_DEVIATION 18.3	94.4 kg STANDARD_DEVIATION 17.6	90.2 kg STANDARD_DEVIATION 15.8
Diabetes	4 Participants	14 Participants	3 Participants	3 Participants	4 Participants
Race and Ethnicity Not Collected	—	0 Participants	—	—	—
Region of Enrollment United States	24 participants	92 participants	22 participants	22 participants	24 participants
Sex: Female, Male Female	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Sex: Female, Male Male	24 Participants	92 Participants	22 Participants	22 Participants	24 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	0 / 24	0 / 24	0 / 22	0 / 22
other Total, other adverse events	20 / 24	21 / 24	21 / 22	15 / 22
serious Total, serious adverse events	2 / 24	2 / 24	0 / 22	1 / 22

Outcome results

Primary